|
| Wednesday, February 15, 2023 |
|
|
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar |
| Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development. more info >> |
|
| Friday, February 10, 2023 |
|
|
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific |
| Novotech, the leading Asia Pacific centred biotech CRO, has published a new global report on Phase 1 trial activity including current metrics on fast growth regions and therapeutic areas. The data analysis found that Asia Pacific has been the fastest-growing region for Phase 1 trials in the last ten years, reaching a share of 58% in 2022, with China leading the Phase I trials globally. more info >> |
|
| Friday, February 3, 2023 |
|
|
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW |
| Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW. The majority of trials are in oncology, specifically for blood cancers, viral infections, and solid tumors. more info >> |
|
| Thursday, January 12, 2023 |
|
|
Novotech Acquires European CRO, Strengthens Global Operations |
| Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program. EastHORN was established in 2004 and has over 250 employees. more info >> |
|
|
Novotech Acquires US-based Drug Development Consulting Firm, CBR International |
| Novotech, the leading Asia Pacific centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversight and strategic regulatory operations group. more info >> |
|
| Tuesday, December 20, 2022 |
|
|
Novotech is Gold Sponsor at Biotech Showcase 2023 |
| Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023. Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference. more info >> |
|
| Thursday, December 15, 2022 |
|
|
Data Shows 50% of New Trials Have Sites in Asia Pacific |
| Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific. more info >> |
|
| Tuesday, December 6, 2022 |
|
|
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials |
| Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry. Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006. more info >> |
|
| Friday, November 11, 2022 |
|
|
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy |
| Novotech, the leading Asia Pacific biotech specialist CRO, is sponsoring BioCentury-BayHelix East-West Summit 2022, and Novotech's Chief Commercial Officer Barry Murphy is Session Chair for the expert panel on How to Build and Finance an East-West MRCT Strategy Workshop at the Summit (14-16 November 2022). more info >> |
|
| Tuesday, October 25, 2022 |
|
|
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper |
| Novotech, the leading Asia Pacific biotech specialist CRO, and GlobalData have published the latest China biotech landscape analysis with expert guidance on pathways to USFDA approval for biotechs conducting research in China. more info >> |
|
|
|
